These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 16637512)

  • 21. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
    Lateef F; Jamal S; Nasir S
    J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
    Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
    Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma.
    El-Hafez AA; El Aaty Shawky A; Hasan B
    Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
    Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
    Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of known prognostic factors in female breast carcinoma including oestrogen receptor, progesterone receptor and Her-2/neu status--a study in a tertiary care centre.
    Chakrabarti S; Karmakar R; Barui G; Maity PK; Bandyopadhyay A; Roy A
    J Indian Med Assoc; 2012 Dec; 110(12):876-9. PubMed ID: 23936949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
    Titi S
    Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER-2 protein overexpressing breast cancer without gene amplification shows higher hormone receptor expression than HER-2 protein overexpressing breast cancer with gene amplification.
    Koo JS; Jung W; Yang WI
    Int J Surg Pathol; 2011 Aug; 19(4):425-32. PubMed ID: 19666946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.
    Boulos F; Farra CG; Saad Aldin EM; Masaad C; Hassoun Y; Fedda F; Doumiati H; Tawil AN; Nasser Z; Nahleh Z; Tfayli A
    J Clin Pathol; 2014 Mar; 67(3):204-9. PubMed ID: 24108431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
    Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
    J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
    Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
    Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
    World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
    Almasri NM; Al Hamad M
    Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma.
    Azam M; Qureshi A; Mansoor S
    J Pak Med Assoc; 2009 Nov; 59(11):736-40. PubMed ID: 20361669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
    Brunello E; Bogina G; Bria E; Vergine M; Zamboni G; Pedron S; Daniele I; Furlanetto J; Carbognin L; Marconi M; Manfrin E; Ibrahim M; Miller K; Tortora G; Molino A; Jasani B; Beccari S; Bonetti F; Chilosi M; Martignoni G; Brunelli M
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1563-8. PubMed ID: 23892410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand.
    Shahi KS; Bhandari G; Singh A
    J Cancer Res Ther; 2011; 7(1):19-22. PubMed ID: 21546737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
    Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
    Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.